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Abstract: BACKGROUND: Congenital melanocytic nevi (CMN) may affect patient quality of life (QoL)
due to medical complications (development of malignant melanoma or involvement of the central nervous
system), skin-related discomfort or psychosocial sequelae. OBJECTIVES: To analyze skin-related QoL
in children and adolescents with CMN and to identify predictors of low QoL. METHODS: Worldwide
recruitment of participants through patient support groups. Data collection through a web-based survey.
QoL was assessed using the Children’s Dermatology Life Quality Indexľ (CDLQI). Demographic and
CMN-related characteristics were examined as possible predictors of impaired QoL. RESULTS: 135 proxy-
reports for children affected by CMN aged between 4-18 years (M = 9.34y, SD = 4.16y) and 28 self-reports
of adolescents aged 14 -18 years (M =16.3y, SD = 1.2y) were included. The mean CDLQI score was 4.00
(SD = 4.39) for proxy-reports and 6.89 (SD = 5.85) for self-reports. Most parents (76%) reported ’no’
or a ’small’ impact, 19% a ’moderate’, and 5% a ’very large’ or ’extremely large’ impact on their child’s
QoL. In self-reports, 46% of the adolescents reported ’no’ or a ’small impact’, 43% a ’moderate’, and
11% a ’very large’ or ’extremely large’ impact. Visible CMN location, malignant melanoma, and higher
child’s age were important predictors of QoL impairments. CONCLUSIONS: Most CMN have a modest
effect on QoL. However, there is large variability with a significant proportion of adolescents experiencing
a moderate to large impact on QoL in contrast to children. Healthcare professionals should be aware of
the predictors of QoL in children with CMN.
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Background: Congenital melanocytic nevi (CMN) may affect patient quality of life (QoL) due to 
medical complications (development of malignant melanoma or involvement of the central nervous 
system), skin-related discomfort or psychosocial sequelae. 
Objectives: To analyze skin-related QoL in children and adolescents with CMN and to identify 
predictors of low QoL. 
Methods: Worldwide recruitment of participants through patient support groups. Data collection 
through a web-based survey. QoL was assessed using the Children’s Dermatology Life Quality Index© 
(CDLQI). Demographic and CMN-related characteristics were examined as possible predictors of 
impaired QoL. 















Results: 135 proxy-reports for children affected by CMN aged between 4-18 years (M = 9.34y, SD = 
4.16y) and 28 self-reports of adolescents aged 14 -18 years (M =16.3y, SD = 1.2y) were included. The 
mean CDLQI score was 4.00 (SD = 4.39) for proxy-reports and 6.89 (SD = 5.85) for self-reports. Most 
parents (76%) reported ‘no’ or a ‘small’ impact, 19% a ‘moderate’, and 5% a ‘very large’ or ‘extremely 
large’ impact on their child’s QoL. In self-reports, 46% of the adolescents reported ‘no’ or a ‘small 
impact’, 43% a ‘moderate’, and 11% a ‘very large’ or ‘extremely large’ impact. Visible CMN location, 
malignant melanoma, and higher child’s age were important predictors of QoL impairments. 
Conclusions: Most CMN have a modest effect on QoL. However, there is large variability with a 
significant proportion of adolescents experiencing a moderate to large impact on QoL in contrast to 
children. Healthcare professionals should be aware of the predictors of QoL in children with CMN.  
 
  


















Congenital melanocytic nevi (CMN) are common birth marks and represent benign 
proliferations of melanocytes. Their incidence ranges between 1 and 6% for small to medium-
sized lesions and around 1 in 20 000 for large CMN, which measure greater than 20 cm in 
diameter in adulthood 1–3. CMN are highly variable in terms of their size, pilosity, color, and 
surface texture. They can occur anywhere on the integument as a single entity or may be 
accompanied by multiple other lesions 3,4.  
Most CMN are uncomplicated, however, pruritus and skin fragility may occur. There is also a 
known risk for the development of malignant melanoma (MM) or central nervous system (CNS) 
abnormalities, both of which can be life threatening. The incidence of MM in patients with 
CMN has been overestimated over decades 5. Recent and more reliable data has shown the 
overall risk of MM to be as low as 0.7% and increasing up to 3.1% in large CMN 6,7. The 
incidence of CNS involvement is inconsistent, however larger size, higher number of satellite 
lesions and multiple CMN are clearly associated with increased occurrence 6,8.  
CMN may affect quality of life (QoL) due to skin-related discomfort (e.g., pain, pruritus, or 
skin fragility), neurological symptoms associated with CNS involvement, or due to complex 
treatment, such as sequential surgical procedures. Moreover, CMN may lead to psychosocial 
difficulties and impaired QoL due to their atypical appearance 8–10. 
The impact of skin diseases on various dimensions of QoL has been well described 10. Most 
reports have investigated common skin conditions such as acne, vitiligo and atopic eczema, but 
there is a paucity of data on QoL for individuals with CMN 10–12. One study has found lower 
health-related QoL in children and adolescents with CMN compared to population norms, but 
generic instruments were used which may lack sufficient sensitivity for dermatology-specific 
impairments 13. To date there is only one study assessing dermatology-specific QoL instruments 















14. This study found an overall low impact on skin-related QoL, but did not analyze potential 
predictors of QoL. 
The aims of this study are to assess patient self- and proxy-reported skin-related QoL in a large 
sample of children and adolescents with CMN and to identify predictors of QoL impairments, 
including general patient as well as CMN specific characteristics. 
 
Patients and Methods 
Study Population:  
The data presented herein is a subset of a large patient recruitment effort assessing QoL and 
psychological adjustment in children and adolescents with CMN. Participants were recruited 
worldwide with the help of CMN patient advocacy and support groups. Furthermore, in 
Switzerland, participants were recruited from the interdisciplinary CMN clinic at the University 
Children’s Hospital Zurich by means of distributing recruitment brochures to eligible families. 
All data points were collected through a web-based survey.  
Patient eligibility criteria were a) self-identification of adolescents with a CMN respectively of 
parents that their child has been diagnosed with a CMN, b) age of the child ≤ 18 years for proxy 
reports and 14 to 18 years for self-reports, and c) adequate knowledge of the English language 
to complete the survey. Partial or complete removal of the CMN was not considered to be a 
criterion for exclusion. Informed consent was obtained electronically prior to starting the 
survey. No personally identifying information was obtained. Proxy- and self-reports were 
collected separately allowing for the possibility that adolescents only, parents only or both 
participated. The Cantonal Ethics Committee from Zurich, Switzerland, gave declaration of no 
objection for this study. 
 
Measures: 















Skin-related QoL: Proxy- and self-reported skin-related QoL was assessed using the CDLQI, 
which is the most widely used instrument to measure the impact of a skin disease on QoL in 
children and adolescents 15. The measure consists of 10 items relating to the week prior (see 
Table 1). Each item is scored on a 4-point Likert scale, ranging from ‘not at all’ (0) to ‘very 
much’ (3). A total score is calculated as the sum of all items (Range: 0-30). Higher scores 
indicate greater QoL impairment. Internal consistency in this study was good for both, proxy- 
(Cronbach’s α= .83) and self-reports (α= .87). As suggested by Waters et al., the following 
severity bands were used: 0–1 ‘no effect’; 2–6 ‘small effect’; 7–12 ‘moderate effect’; 13–18 
‘very large effect’; 19–30 ‘extremely large effect’ on QoL16. 
Surgery: Respondents were asked whether the CMN had been managed surgically. Possible 
answers were: no surgery, partial removal, or full removal. For multivariate analyses, a 
dichotomous variable (full removal yes/no) was used. 
Location and extent of the skin lesion: Respondents were presented a figure of a child, in which 
the body surface area was divided into 122 squares of the same size. They were asked to indicate 
how many squares were affected by the CMN or by a scar resulting from a nevus excision. The 
number of affected squares was assessed separately for the following body parts: face, scalp, 
neck, collar, arms/shoulders, hands, chest, abdomen/flank, back/buttocks, and legs/feet. A score 
for the body surface area (BSA) affected by the skin lesion was computed as sum of all affected 
squares (potential range 0-122). For multivariate analyses, dichotomous variables were used, 
indicating whether a specific body part was affected by the skin lesion or not. 
Health status: Respondents were asked to indicate any chronic health condition as well as any 
of the following CMN-related health problems: malignant transformation of the nevus, 
neurocutanous melanocytosis, and neurological problems.  
Skin-related symptoms: Intensity of the following symptoms over the past few weeks was rated 
on a 5-point Likert scale, ranging from 0 (no problem) to 4 (very severe): pain, pruritus, dryness, 
skin fragility, bleeding, and hypohidrosis.  















Socioeconomic status (SES): SES was assessed using the MacArthur Scale of Subjective Social 
Status. Assessment of subjective ratings of familial placement in society was carried out as 
proposed by Goodman et al. 17. Three social classes were defined as follows: lower SES (0-4), 
middle SES (5-7), and upper SES (8-10). For statistical analysis, the raw score (possible range 
0-10) was used. Further demographic information included age, sex, and country of residence. 
 
Statistical analyses:  
SPSS software (Version 24, IBM Corporation, 2016) was used for data analysis. Two-sided 
tests were used for all analysis and a value of p < .05 was considered significant. Post hoc power 
analyses (α = .05, two-tailed) were performed using the G*power software 18. For proxy-reports 
our sample size (n=135) provided good power (>.92) to detect medium to large effect sizes (ρ 
= 0.3, f2 ≥ 0.15) in bivariate correlations and regression analyses, but not enough power to 
detect small effect sizes (ρ = 0.1, f2 ≤ 0.02). For self-reports (n=28), power was acceptable (.79) 
to detect large effects (ρ = 0.5) in bivariate correlations, but not enough to detect small or 
medium effect sizes. Notably, the sample size of self-reports was too small to perform multiple 
regression analyses. Bivariate Pearson correlations were conducted with all possible predictor 
variables and the following outcome variables: self- and proxy-reported (1) CDLQI total score, 
(2) CDLQI item 2: ‘Feeling embarrassed, self-conscious, upset or sad because of the skin’, and 
(3) CDLQI item 3: ‘Calling names, teasing, bullying, asking questions, or avoiding’. 
Subsequently, for proxy-reports, predictors with p< .05 were analyzed using multivariate 




Sample Characteristics:  















A total of 136 parent proxy reports were received. A single report was excluded from further 
analysis because parents reported a severe health condition which had a greater impact on their 
child’s life than the CMN, leading to a final sample of 135 proxy reports. With respect to self-
reports, two cases were excluded for the same reason as above, resulting in a total sample of 28 
self-reports. Table 2 shows detailed sample characteristics for proxy and self-reports. Proxy 
reports were mainly provided by the mother (88%), followed by the father (7%), by both parents 
(4%), or by a grandmother (2%). 
Table 3 shows the frequencies of self- and proxy reported skin-related symptoms. The highest 
incidence were found for dryness in proxy reports and pruritus in self-reports. 
 
Skin-related QoL:  
Analysis of CDLQI demonstrated that all aspects of QoL were affected to some degree by the 
skin lesion in both, proxy as well as self-reports (Table 1). The highest ratings in proxy reports 
were found for ‘itchy/painful skin’ (Q1) and ‘being called names/teasing’ (Q8), whereas in self-
reports the greatest impact was reported for ‘feeling embarrassed/self-conscious’ (Q2) and 
‘clothing decisions’ (Q4). Mean CDLQI total score was 4.00 (SD = 4.39) in parent-reports and 
6.89 (SD = 5.85) in self-reports.  
The range of scores demonstrated large variability, with 19% of parents and 43% of adolescents 
reporting a ‘moderate effect’ and 5% of parents and 11% of adolescents reporting a ‘very large’ 
or ‘extremely large’ effect on QoL, respectively (Table 4). 
 
Predictors of skin-related QoL:  
Bivariate Correlations between potential predictor variables and QoL outcomes are shown in 
Table 5. Table 6 summarizes statistics for three regression models predicting proxy-reported 
QoL outcomes. The selected predictors accounted for 12% of the variance in the CDLQI total 
score, 15% for ‘feeling embarrassed, self-conscious, upset, or sad because of the skin’, and 14% 















for experiencing ‘name calling, teasing, bullying, questions, or avoiding’. Impairment of total 
skin-related QoL was significantly predicted by occurrence of MM and CMN located on hands. 
Feeling self-conscious/upset was predicted by increasing age of a child, occurrence of 
melanoma, and CMN located on the hands or face. Involvement of the hands or face were also 
significant predictors for experiencing stigmatization, such as teasing, name calling, bullying, 
questioning or avoiding.  
 
Discussion 
The first aim of this study was to assess self- and proxy-reported skin-related QoL in children 
and adolescents affected by CMN. Proxy as well as self-reports showed that CMN affect all 
aspects of QoL as measured by the CDLQI. The average overall impact of CMN on QoL was 
found to be rather small, especially in parent-reports. The variance in the total CDLQI score, 
however, was large, with 24% of parents and 54% of adolescents reporting a ‘moderate’ to 
‘extremely large’ effect on QoL. A direct comparison of proxy- and self-reports is not possible 
in this study due to significant differences in the sample population, including age range and 
CMN characteristics. 
Many skin diseases have been shown to have an impact on QoL that is comparable to other 
severe  medical conditions, such as cancer, heart disease, and diabetes 10,11,19. Our results are in 
line with those of Wramp et al. 14 who published the only other study on skin-related QoL in 
individuals with CMN  . They analyzed a cohort of 55 individuals with CMN aged 4 years to 
adulthood and also found large variability of scores and similar overall impact on QoL, with 
about 20% moderate to severe impact. Their study participants, however, were recruited 
through a German CMN patient support group resulting in a small sample that is limited to a 
specific geographical region unlike our study population, which is considerably larger and 
encompasses patients from all over the world.  















Olsen et al. performed a meta-analysis of studies using the CDLQI questionnaire to assess the 
impact of a skin disease on QoL in children 10. Most of the 67 publications included in the study 
focused on common dermatological conditions, such as acne, atopic eczema, or vitiligo. The 
mean score across all studies showed a ‘small effect’ on QoL similar to our results. When 
comparing different skin conditions, the authors found a ‘small’ impact on QoL for acne, 
vascular anomalies, vitiligo and warts, with mean scores similar to that in our CMN sample. 
Mean scores for atopic eczema and psoriasis, on the other hand, were considerably higher 
indicating a ‘moderate’ impact on QoL. These higher scores can be reconciled when 
considering that the aforementioned conditions show a fluctuating course with unpredictable 
flare-ups, causing significant itch, sleep disturbance, and a varying degree of aesthetic 
impairment. This stands in contrast with conditions such as CMN, which usually cause little or 
no physical symptoms and generally carry a stable clinical course. In our study, the largest 
effect on QoL reported in self-reports was for clothing decisions and ‘feeling embarrassed, self-
conscious, upset or sad because of the skin’, suggesting that CMN may cause an emotional 
rather than a functional impairment of QoL in adolescents. This finding is in line with the results 
of our previous study assessing generic health-related QoL in children and adolescents with 
CMN 13. 
 
Addressing our second study goal, this study is the first to identify predictors of impaired 
dermatology-specific QoL in children and adolescents with CMN, namely occurrence of MM 
and visible CMN location (hands and face). Of note, other variables, such as gender, complete 
removal of the CMN or extent of the skin lesion did not predict QoL outcomes. Feeling self-
conscious/upset was predicted by higher child age, reported occurrence of MM, and CMN 
located on the hands or face. Involvement of the hands or face was also a significant predictor 
for experiencing stigmatization. These results are in line with previous findings 9,19,20 suggesting 
that lesions on visible body parts, are associated with experiences of stigmatization, including 















intrusive questions, teasing, and bullying. Such experiences might lead to feelings of self-
consciousness and impairments of psychosocial functioning 9. Increasing feelings of self-
consciousness and embarrassment with higher age can be explained, when considering that 
infants may be too young to be aware of the social implications of their condition. Difficulties 
may arise in early school years when children increasingly engage in social comparisons with 
peers and in adolescence when appearance and peer acceptance are of utmost importance. 
Accordingly, previous studies found higher QoL impairments in adolescents compared to 
younger children 12,14.  
Although we identified visibility as a predictor of impaired QoL, many previous publications 
found no direct effect of size and visibility of a skin lesion on generic health related QoL or 
psychological adjustment 21. There are, however, reports suggesting an indirect effect through 
stigmatization 13. The identification of a direct effect in our study may be explained by the 
utilization of a dermatology-specific instrument for measuring QoL. The CDLQI includes 
specific questions addressing clothing decision, staring, going out/swimming, and hobbies, 
which are likely influenced by the visibility of the skin lesion.  
 
The strengths of the presented study are the large sample size, the inclusions of children and 
adolescents with a broad spectrum of CMN sizes and irrespective of their previous medical 
treatment, the assessment of proxy- as well as self-reports, the use of a well-known 
dermatology-specific QoL instrument, and the analysis of possible predictors of skin-related 
QoL. However, some limitations merit note. First, the cross-sectional design prevents any 
conclusions about causal relations. Second, the recruitment of participants through patient 
advocacy and support groups might have led to a selection bias, as it could be that individuals 
experiencing more difficulties are more likely to be involved in such organizations. Further, the 
overall sample size for self-reports was too small to allow multivariate analysis. Proxy reports 
included a large age range (4-18 years), but the sample size was too small for age-dependent 















subgroup analysis. Such analyses would be of value as it is likely that challenges related to a 
skin condition vary throughout different developmental periods, such as preschoolers and 
adolescents. Finally it must be noted that we included children ages 4 to 18 years, which extends 
beyond the initial CDLQI design for children ages 4 to 16 years 15. 
 
Our results have significant clinical implications. About 11% of adolescents reported a ‘very 
large’ to ‘extremely large effect’ on their QoL. This highlights the importance of screening for 
QoL impairment in the clinical assessment of patients with CMN. Identified predictors of QoL 
help to recognize patients at highest risk for difficulties. Such patients may benefit from 
referrals to psychosocial specialists. Knowledge and awareness of potential QoL impairment in 
children and adolescents with CMN can improve patient guidance and management. This is 
especially important since CMN are no longer treated with surgical excision as the standard 
treatment to reduce a previously overestimated risk of malignancy. Instead, families’ interest 
to have surgery are rooted in aesthetic and psychosocial considerations in most cases. 
Psychological assessments should be integrated in clinical management as they can impact 
proposed medical treatment strategies. Furthermore, patient advocacy and support groups might 
be an important source of information and social support for patients and families.  
 
Future research should include longitudinal data, analyze developmental effects, and address 
psychosocial consequences of treatment decisions (e.g. surgical removal of a CMN) as well as 
satisfaction with treatment. Since identified predictors in this study only account for little 
variance in QoL outcomes, the search for other predictors should be continued.  
 
In conclusion, overlooking the largest sample size of children and adolescents with CMN 
assessed so far, this study provides evidence that CMN impact on skin-related QoL in children. 
Although the overall impairment appears to be small, the range is wide with a considerable 















number of adolescents experiencing a large effect. Screening for QoL impairment should 
therefore be included in the evaluation of children with CMN and be incorporated into 
therapeutic decision making. Further research, ideally longitudinal, is needed to gain more 
insights into the mechanisms underlying QoL impairments and psychosocial adjustment in 
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Table 1: Impact of the skin lesion on different aspects of quality of life according to proxy- and self-reports. 
 Proxy reports (N = 135)  Self-reports (N = 28) 




















Q1. Itchy, “scratchy”, sore or painful skin 51.1 37.8 9.6 1.5 0.61 (0.72)  44.4 37.0 14.8 3.7 0.78 (0.85) 
Q2. Embarrassed, self-conscious, upset or sad 
because of skin 
60.7 29.6 5.2 4.4 0.53 (0.79)  17.9 57.1 14.3 10.7 1.18 (0.86) 
Q3. Friendships 76.3 20.0 2.2 1.5 0.29 (0.58)  71.4 25.0 3.6 0 0.32 (0.56) 
Q4. Clothing decisions 63.7 21.5 11.1 3.7 0.55 (0.84)  33.3 33.3 18.5 14.8 1.48 (1.06) 
Q5. Going out, playing, or hobbies 75.6 17.8 4.4 2.2 0.33 (0.67)  57.1 28.6 7.1 7.1 0.64 (0.91) 
Q6. Swimming or other sports 80.7 11.1 4.4 3.7 0.31 (0.73)  50.0 21.4 7.1 21.4 1.00 (1.22) 
Q7. Schoolwork/Holiday in past week 84.4 15.6 0 0 0.16 (0.36)  71.4 10.7 14.3 3.6 0.52 (0.89) 
Q8. Calling names, teasing, bullying, asking 
questions, or avoiding 
59.3 30.4 4.4 5.9 0.57 (0.83)  50.0 35.7 10.7 3.6 0.68 (0.82) 
Q9. Sleep 82.2 11.1 5.2 1.5 0.26 (0.62)  82.1 14.3 3.6 0 0.21 (0.50) 
Q10. Effect of treatment on quality of life 70.4 23.0 4.4 2.2 0.39 (0.68)  60.7 28.6 10.7 0 0.50 (0.69) 
CDLQI Total sum score     4.00 (4.39)      6.89 (5.85) 
Note. Frequencies are reported in case percentages. CDLQI = Children`s Dermatology Quality of Life Index. 
 
 



















(N = 28) 
Sex   
 Female 72 (53.3%) 25 (89.3%) 
 Male 63 (46.7%) 3 (10.7%) 
Age, years   
 Mean (SD) 9.34 (4.16) 16.3 (1.2) 
 Range 4-18 14-18 
Socioeconomic status, M (SD) 6.81 (1.46) 6.4 (4.9) 
 Lower (0-4) 7 (5.2%) 3 (10.7%) 
 Middle (5-7) 72 (60.7%) 18 (64.3%) 
 Upper (8-10) 46 (34.1%) 7 (25.0%) 
Country of residence   
 Europe (total)   
 Great Britain (UK, Ireland) 20 (14.8%) 4 (14.3%) 
 Germany and Switzerland 23 (17.0%) 3 (10.7%) 
 Southern Europe  5 (3.6%) 5 (17.8%) 
 Belgium and The Netherlands 7 (5.2%) 2 (7.1%) 
 Scandinavia 6 (4.5%) 0 
 Other European countries 5 (3.7%) 1 (3.6%) 
United States and Canada 55 (40.8%) 7 (25%) 
South America  








Asia  4 (3.0%) 1 (3.6%) 
Not provided n.a. 1 (3.6%) 
Previous surgical excision of CMN   
None 49 (36.3%) 9 (32.1%) 
Partial removal of CMN 72 (53.3%) 16 (57.1%) 
Full removal of CMN 14 (10.4%) 3 (10.7%) 
Location of the skin lesion   
 Face 49 (36.6%) 9 (32.1%) 
 Scalp 45 (33.6%) 8 (28.6%) 
 Neck 23 (17.1%) 7 (25.0%) 
 Collar 19 (14.2%) 3 (10.7%) 
 Arms/shoulders 43 (32.1%) 8 (28.6%) 























Table 3: Frequency of proxy- and self-reported skin-related symptoms. 
 Proxy-reports (N = 133-135)  Self-reports (N = 27-28) 

















Pain 85.8 13.4 0.7 0 0.15 (0.38)  74.1 25.9 0 0 0.26 (0.45) 
Itchiness 46.7 49.6 3.0 0.7 0.58 (0.59)  46.4 42.9 10.7 0 0.64 (0.68) 
Dryness 37.8 51.9 8.1 2.2 0.75 (0.70)  53.6 39.3 7.1 0 0.54 (0.64) 
Skin fragility 50.4 42.1 5.3 1.5 0.57 (0.67)  57.1 35.7 7.1 0 0.57 (0.84) 
Bleeding 85.7 12.0 1.5 0.8 0.17 (0.47)  78.6 21.4 0 0 0.21 (0.42) 
Decreased 
sweating 
55.6 33.1 7.5 3.8 0.59 (0.79)  64.3 35.7 0 0 0.36 (0.49) 
Note. Frequencies are reported in valid case percentages  
 
 
 Hands 22 (16.4%) 4 (14.3%) 
 Chest 37 (27.6%) 7 (25.0%) 
 Abdomen 53 (39.6%) 11 (39.3%) 
 Back 87 (64.9%) 20 (71.4%) 
 Legs/feet 64 (47.8%) 18 (64.3%) 
 Genitals 32 (23.9%) 6 (21.4%) 
BSA score    
 Mean, SD 13.63 (16.92) 16.11 (24.23) 
 Range 1-112 1-106 
CMN associated medical conditions   
 Central nervous system involvement  14 (10.6%) n.a. 
 Neurological problems 16 (11.9%) n.a. 
 Malignant melanoma 4 (3.0%) n.a. 
Other chronic health conditions   
 Asthma 5 (3.6%) 5 (18.0%) 
 Allergies 14 (10.3%) 6 (20.0%) 
 Eczema 3 (2.1%) 1 (3.6%) 





















Table 4: Impact of congenital melanocytic nevi on skin-related quality of life (CDLQI total score). 
 Proxy-reports for children ages 4-18 years 
(N =135) 
 Self-reports of adolescents  
ages 14-18 (N= 28) 
 n %  n % 
No effect (0-1) 54 40.0%  7 25.0% 
Small effect (2-6) 49 36.3%  6 21.4% 
Moderate effect (7-12) 25 18.5%  12 42.9% 
Very large effect (13-18) 6 4.4%  1 3.6% 
Extremely large effect (19-30) 1 0.7%  2 7.1% 




Table 5: Bivariate correlations between predictor variables and quality of life outcomes. 
 Proxy-reports (n = 134-135)  Self-Reports (n = 27-28) 












Variable r p  r p  r p  r p  r p  r p 
Age of child .12 .17  .20 .02  .07 .41  .50 <.01  .32 .09  .32 .10 
Male sex of child  -.07 .46  -.05 .57  -.07 .42  -.13 .50  -.21 .29  -.15 .45 
Socioeconomic status -.20 .02  -.09 .29  -.11 .20  -.49 <.01  -.44 .02  -.23 .24 
Melanoma -.25 <.01  -.22 .01  -.04 .65  n.a.  n.a.  n.a. 
NCM -.13 .15  -.02 .81  -.22 .01  n.a.  n.a.  n.a. 
Neurological problems -.07 .40  .05 .61  -.14 .12  n.a.  n.a.  n.a. 
Complete surgical removal of 
CMN 
-.05 .56  -.05 .60  .00 .99  -.19 .32  -.45 .07  -.01 .98 
Location of the skin lesion                  
 Face .15 .09  .19 .03  .31 <.001  .12 .55  .31 .11  .18 .36 
 Scalp .15 .09  .10 .27  .20 .02  -.09 .67  -.02 .93  -.21 .89 
 Neck .07 .45  .07 .45  .08 .35  -.05 .80  -.10 .61  -.04 .83 
 Collar .01 .93  .02 .81  .04 .64  -.09 .66  -.20 .32  -.14 .50 
 Arms/shoulders .10 .27  .06 .50  .16 .06  .39 <.05  .27 .17  .10 .62 
 Hands .27 <.01  .24 <.01  .37 <.001  .70 <.001  .54 <.01  .33 .09 
 Chest .02 .82  -.04 .65  .16 .07  -.05 .80  -.10 .61  -.04 .83 
 Abdomen .14 .10  .01 .91  .11 .21  .30 .13  .26 .18  .14 .48 
 Back .08 .35  -.02 .87  .06 .51  .21 .29  .13 .50  -.06 .78 
 Legs/feet .05 .59  .05 .57  .11 .23  .27 .16  .25 .21  -.02 .92 
 Genitals .06 .52  -.00 .96  .02 .79  .64 <.001  .51 <.001  .44 .02 
TBSA score .11 .20  .08 .39  .16 .07  .73 <.001  .56 <.01  .36 .06 
Note. CDLQI = Children`s Dermatology Quality of Life Index. NCM = neurocutanous melanocytosis. CMN= Congenital melanocytic nevus. TBSA = Total 
body surface affected by the CMN. n.a. = not available 



















Table 6: Summary of multiple regression analyses predicting proxy-reported skin-related quality of life outcomes. 
 
Model 1  
CDLQI total score 
 Model 2:  
Self-consciousness/ Feeling upset 
 Model 3: 
Teasing / Questions 
Variable B SEB β p  B SEB β p  B SEB β p 
Age of child 0.11 0.09 .10 .22  0.04 0.02 .20 .02  0.01 0.02 .04 .61 
Socioeconomic status -0.48 0.26 -.16 .06  -0.03 0.05 -.05 .52  -0.05 0.05 -.10 .24 
Malignant melanoma -6.35 2.45 -.22 .01  -1.33 0.44 -.25 <.01  0.47 0.43 .10 .28 
Neurocutaneous melanocytosis -1.16 1.30 -.08 .37  -0.05 0.23 -.02 .82  -0.18 0.23 -.07 .44 
Face  1.17 0.77 .13 .13  0.31 0.14 .19 .03  0.40 0.14 .25 <.01 
Scalp -0.15 0.84 -.02 .86  -0.06 0.15 -.04 .70  0.04 0.15 .02 .82 
Hands  2.80 1.07 .23 .01  0.53 0.19 .24 <.01  0.54 0.19 .25 <.01 
Note.  Model 1: R = .41 (n = 130, p < .01), R2 = .17, R2 adj. = .12. Model 2: R = .44 (n = 130, p < .001), R2 = .20, R2 adj. = .15. Model 3: R = .43 (n = 130, p < 
.001), R2 = .18, R2 adj. = .14. CDLQI = Children`s Dermatology Quality of Life Index. 
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